What is HC Wainwright’s Estimate for Septerna Q1 Earnings?

Septerna, Inc. (NASDAQ:SEPN) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for Septerna in a research report issued to clients and investors on Wednesday, March 11th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.75) for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna’s Q2 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.81) EPS and Q4 2027 earnings at ($0.88) EPS.

SEPN has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $60.00 target price on shares of Septerna in a report on Tuesday. Zacks Research upgraded Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Truist Financial lifted their price target on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Wells Fargo & Company increased their price objective on Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Septerna currently has an average rating of “Moderate Buy” and an average price target of $44.00.

Septerna Stock Up 0.5%

Shares of NASDAQ:SEPN opened at $26.44 on Thursday. The stock has a market cap of $1.19 billion, a PE ratio of -23.82 and a beta of 3.46. The company’s fifty day moving average is $26.83 and its 200 day moving average is $23.30. Septerna has a 52 week low of $4.66 and a 52 week high of $32.63.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%. The business had revenue of $24.12 million during the quarter, compared to analysts’ expectations of $20.44 million.

Insider Transactions at Septerna

In other Septerna news, insider Samira Shaikhly sold 70,453 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the completion of the transaction, the insider owned 793 shares of the company’s stock, valued at $22,283.30. This represents a 98.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total value of $115,880.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Septerna

Several hedge funds have recently made changes to their positions in SEPN. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Septerna by 116.7% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 222,702 shares of the company’s stock valued at $2,354,000 after acquiring an additional 119,953 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Septerna in the 4th quarter worth $53,000. Russell Investments Group Ltd. purchased a new stake in shares of Septerna in the 3rd quarter worth about $36,000. Global Retirement Partners LLC purchased a new stake in shares of Septerna in the 4th quarter worth about $35,000. Finally, Seven Fleet Capital Management LP bought a new stake in shares of Septerna during the 4th quarter valued at about $319,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.